Background
Influenza and respiratory syncytial virus (
RSV
) infections are responsible for substantial global morbidity and mortality in young children and elderly individuals. Estimates of the burden of influenza‐ and
RSV
‐associated hospitalization are limited in Africa.
Methods
We conducted hospital‐based surveillance for laboratory‐confirmed influenza‐ and
RSV
‐associated severe acute respiratory illness (
SARI
) among patients of any age at one hospital and a retrospective review of
SARI
hospitalizations in five hospitals situated in Antananarivo during 2011‐2016. We estimated age‐specific rates (per 100 000 population) of influenza‐ and
RSV
‐associated
SARI
hospitalizations for the Antananarivo region and then extrapolated these rates to the national level.
Results
Overall, the mean annual national number of influenza‐associated
SARI
hospitalizations for all age groups was 6609 (95%
CI
: 5381‐7835‐rate: 30.0; 95%
CI
: 24.4‐35.6), 4468 (95%
CI
: 3796‐5102‐rate: 127.6; 95%
CI
: 108.4‐145.7), 2141 (95%
CI
: 1585‐2734‐rate: 11.6; 95%
CI
: 8.6‐14.8), and 339 (95%
CI
: 224‐459‐rate: 50.0; 95%
CI
: 36.3‐74.4) among individuals aged <5, ≥5, and ≥65 years, respectively. For these same age groups, the mean annual number of
RSV
‐associated
SARI
hospitalizations was 11 768 (95%
CI
: 10 553‐12 997‐rate: 53.4; 95%
CI
: 47.9‐59.0), 11 299 (95%
CI
: 10 350‐12 214‐rate: 322.7; 95%
CI
: 295.6‐348.8), 469 (95%
CI
: 203‐783‐rate: 2.5;95%
CI
: 1.1‐4.2), and 36 (95%
CI
: 0‐84‐rate: 5.8; 0.0‐13.5), respectively.
Conclusion
The burden of influenza‐ and
RSV
‐associated
SARI
hospitalization was high among children aged <5 years. These first estimates for Madagascar will enable government to make informed evidence‐based decisions when allocating scarce resources and planning intervention strategies to limit the impact and spread of these viruses.
The burden of influenza- and RSV-associated SARI hospitalization was high among children aged <5 years. These first estimates for Madagascar will enable government to make informed evidence-based decisions when allocating scarce resources and planning intervention strategies to limit the impact and spread of these viruses. This article is protected by copyright. All rights reserved.
Background: Following the first detection of SARS-CoV-2 in passengers
arriving from Europe on 19 March 2020, Madagascar took several
mitigation measures to limit the spread of the virus in the country.
Methods: Nasopharyngeal and/or oropharyngeal swabs were collected from
travellers to Madagascar, suspected SARS-CoV-2 cases, and contact of
confirmed cases. Swabs were tested at the national reference laboratory
using real-time RT-PVR. Data collected from patients were entered in an
electronic database for subsequent statistical analysis. All
distribution of laboratory confirmed cases were mapped and six genomes
of viruses were fully sequenced. Results: Overall, 26,415 individuals
were tested for SARS-CoV-2 between 18 March and 18 September 2020, of
whom 21.0% (5,553/26,145) returned positive. Among laboratory-confirmed
SARS-CoV-2 positive patients, the median age was 39 years (CI95%:
28-52), and 56.6% (3,311/5,553) were asymptomatic at the time of
sampling. The probability of testing positive increased with age with
the highest adjusted odds ratio of 2.2 [95% CI: 1.9-2.5] for
individuals aged 49 years and more. Viral strains sequenced belong to
clades 19A, 20A, and 20B in favour of several independent introduction
of viruses. Conclusions. Our study describes the first wave of the
COVID-19 in Madagascar. Despite early strategies in place Madagascar
could not avoid the introduction and spread of the virus. More studies
are needed to estimate the true burden of disease and make public health
recommendations for a better preparation to another wave.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.